The 2019 AAD Annual Meeting was filled with broad innovations covering the entire field of dermatology. In this report, you will find several highlights.
Innovation in dermatology is no longer limited to a few areas. For example, innovations in psoriasis have expanded to atopic dermatitis, hidradenitis suppurativa, urticaria, and vitiligo. Important innovations are biologics with different targets but also small molecules, including Janus kinase inhibitors. In particular, several IL-17 and IL-23 blockers have opened new perspectives for long-term control of psoriasis. Anti-IL-4 and IL-13 are the new options for the treatment of atopic dermatitis.
Also covered in this conference report are new leads on hair loss, vitiligo, and non-me...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Interview with AAD president Prof. George J. Hruza Next Article
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies »